Project Grant R01CA305969
Award Date 5/22/26
Completion Date 4/30/31
Dollars Obligated $717K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Project Grant Award Summary The National Cancer Institute awarded $1,034,176 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, for a project extending through July 31, 2032. The research focuses on understanding and targeting aberrant RNA splicing in leukemia, building on the principal investigator's 13-year track record of discovering genetic alterations in hematopoietic malignancies. The project aims to...
- Federal Grant Award Summary New York University School of Medicine received a $585,482 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026 through May 31, 2031. This five-year research award supports fundamental investigations into the molecular mechanisms of breast cancer metastasis, specifically examining the dual role of the translation factor DAP5 (Death-Associated Protein 5) in selective messenger RNA...
- Federal Project Grant Award Summary New York University School of Medicine received a $695,852 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded on May 1, 2026, with a completion date of April 30, 2031. The award funds fundamental research investigating T cell circuits in the lymphatic system during melanoma progression, specifically examining tumor-draining lymph nodes (TDLNs) as key immune surveillance hubs. The research...
- Federal Grant Award Summary New York University School of Medicine received a $466,125 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), awarded May 14, 2026, with completion targeted for April 30, 2028. The grant funds fundamental research investigating the role of incretin mimetics in reducing the risk of development and progression of multiple myeloma (MM) and its precursor condition, monoclonal gammopathy of undetermined significance...
- Federal Project Grant Award Summary New York University School of Medicine received a $217,600 project grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) awarded on September 26, 2025, with a completion date of March 31, 2029. The award supports research training and investigator development in cancer biology, specifically focused on understanding T cell acute lymphoblastic leukemia (T-ALL) infiltration into the central nervous system (CNS)....
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded New York University School of Medicine a $2,013,199 Project Grant effective September 1, 2025, through November 30, 2029, under the Cancer Treatment Research program (CFDA 93.395). This award supports the expansion of NCI-sponsored clinical research in hematologic malignancies to Brooklyn and Queens through the Perlmutter Cancer Center (PCC). The PCC will oversee a robust portfolio of clinical trials across national networks...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $501,422 to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Cancer Biology Research program (CFDA 93.396). The award, effective May 1, 2026 through April 30, 2031, funds fundamental research aimed at validating and characterizing a novel synthetic lethal therapeutic target for precision cancer treatment. The research focuses on the PELO-HBS1L...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Missouri System $486,426 under the Cancer Biology Research program (CFDA 93.396) to conduct a five-year research project examining leukemic stem cell (LSC) interactions within the bone marrow microenvironment (niche) and developing niche-directed leukemia treatments. The research initiative, which commenced April 1, 2026 and concludes March 31, 2031, focuses on elucidating molecular crosstalk...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period of April 1, 2026 through March 31, 2028. The award supports research investigating dual-targeting therapeutic approaches for acute myeloid leukemia (AML) through the combination of BCL-2 inhibition and CD123-directed natural killer (NK) cell engagement. The research will evaluate the...